Compare AQST & ALTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AQST | ALTI |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | 490 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.0M | 407.2M |
| IPO Year | 2007 | 2021 |
| Metric | AQST | ALTI |
|---|---|---|
| Price | $4.24 | $3.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 149.9K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.11 |
| EPS | N/A | ★ N/A |
| Revenue | $67,430,000.00 | ★ $254,956,000.00 |
| Revenue This Year | $10.08 | $18.06 |
| Revenue Next Year | $49.60 | $10.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.77 | ★ 23.21 |
| 52 Week Low | $2.22 | $2.96 |
| 52 Week High | $7.55 | $5.45 |
| Indicator | AQST | ALTI |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 41.09 |
| Support Level | $3.70 | $3.31 |
| Resistance Level | $4.35 | $3.96 |
| Average True Range (ATR) | 0.14 | 0.22 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 55.56 | 37.34 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.